<\/p>
Syngene International\u00a0reported a 20% decline in FY26 profit despite a 3% rise in revenue, as business from a single large biologics client weighed on performance, with margins also impacted by additional operating costs.<\/p>
Revenue from operations rose to Rs. 3,739 crore in FY26 from Rs. 3,642 crore a year earlier, but operating EBITDA fell 12% to Rs. 918 crore, pulling margins down to 25% from 29%. Profit after tax (before exceptional items) declined to Rs. 380 crore, while reported profit after exceptional items stood at Rs. 317 crore.<\/p>
The fourth quarter reflected similar pressures, even as sequential momentum improved. Revenue rose 2% year-on-year to Rs. 1,037 crore and 13% quarter-on-quarter. Operating EBITDA declined 12% to Rs. 303 crore, with margins at 29% compared to 34% a year earlier. Profit after tax (before exceptional items) dropped 16% to Rs. 153 crore, while reported profit after exceptional items was Rs. 148 crore.<\/p>
The company attributed the performance to the impact of its largest biologics customer.<\/p>
\u201cSyngene\u2019s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum,\u201d said Peter Bains, Managing Director and CEO.<\/p>
Chief Financial Officer Deepak Jain said the pressure on margins also reflects \u201cadditional operating costs as we bring the new biologics manufacturing facility in India into operations.\u201d<\/p>
The company generated Rs. 521 crore in net cash during the year after capital expenditure.<\/p>
Exceptional items during the year included the impact of revised labour codes leading to higher gratuity liabilities, expenses related to employee termination benefits, and an insurance settlement.<\/p>
Operationally, the company expanded capabilities in antibody-drug conjugates (ADCs), commissioning an ADC discovery laboratory during the quarter, and continued investments in emerging modalities such as peptides and ADCs.<\/p>
It completed 85 client and regulatory audits during the year and secured GCP-NABL accreditation.
The board has recommended a final dividend of Rs. 1.25 per share for FY26.<\/p> <\/div>
#Syngenes #FY26 #profit #falls #biologics #client #impact #weighs #margins1777478036<\/p> ","protected":false},"excerpt":{"rendered":"
Syngene International\u00a0reported a 20% decline in FY26 profit despite a 3% rise in revenue, as business from a single large biologics client weighed on performance, with margins also impacted by additional operating costs. Revenue from operations rose to Rs. 3,739 crore in FY26 from Rs. 3,642 crore a year earlier, but operating EBITDA fell 12% […]<\/p>\n","protected":false},"author":1,"featured_media":7443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[27737,27738,1870,1770,409,2214,1129,27736,181],"class_list":["post-7442","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-content-marketing","tag-biologics","tag-client","tag-falls","tag-fy26","tag-impact","tag-margins","tag-profit","tag-syngenes","tag-weighs"],"acf":[],"_links":{"self":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/7442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7442"}],"version-history":[{"count":0,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/7442\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/media\/7443"}],"wp:attachment":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7442"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}